ORGONasdaqPharmaceutical PreparationsFiscal year ends December 31
Organogenesis Holdings Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$1.02+0.02 (+2.03%)
Close on Oct 19, 2026
- Market cap
- $131.25M
- P/E (TTM)
- –
- Dividend yield
- –
Organogenesis Holdings Inc. revenue by segment
By business segment
By product or service
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Product Revenue | $454.61M | $512.59M | $563.03M | $464.62M | $429.31M | $458.76M | $482.04M | – | – | – | – | – | 99.4% | +5.9% |
| Grant [Member] | $2.84M | $2.12M | $1.14M | $603.00K | $226.00K | $0 | $0 | – | – | – | – | – | 0.6% | +1157.1% |
| Advanced Wound Care | – | – | – | – | – | $429.70M | $453.64M | $428.22M | $421.62M | $408.46M | $405.51M | $421.19M | – | – |
| Surgical & Sports Medicine | – | – | – | – | – | $29.06M | $28.40M | $26.82M | $26.77M | $27.01M | $27.63M | $27.82M | – | – |
By region
From the segment and revenue-disaggregation notes of Organogenesis's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.